BioGroup - Changing Risk Reward - Model Update
All,
Please find our updated analysis on BioGroup here.
Following the investor day in January, the reported numbers are not, in isolation, credit-relevant. That said, revenue and EBITDA came in modestly below our expectations, while free cash flow exceeded our forecasts due to lower capex and stronger working-capital management. As the maturity profile comes into focus, our credit view increasingly depends on the structure's refinancability in Q3 2027. BioGroup has benefited from historically low coupon rates across both senior and subordinated debt, and any refinancing will take place at meaningfully higher interest costs. While we still view refinancing as achievable, current bond levels offer an increasingly unfavourable risk-reward profile.
Investment Rationale
- We will exit our 3% long position in the senior unsecured bonds at c.94% next week, when liquidity returns to the market. We initiated the position in December 2025 at 81%. Although we continue to expect a par refinancing in late 2027, current yields no longer compensate adequately for the risks.
- We deliberately sized the position conservatively due to the asymmetric downside. The unsecured bonds represent a relatively small tranche beneath a large senior debt stack. While unlikely, a refinancing could require subordinated holders to extend maturities. A more material risk is potential headline risk from proposed changes to pricing dynamics by the French government; under such a scenario, and given the low coupon, the bonds could decline by up to 10 points.
- Upside from current levels remains limited, with a pull to par of approximately 6 points. Given the low coupon and the low probability of a refinancing ahead of Q3 2027, upside appears constrained. A sale of the business could accelerate value realisation, but we view this as a low-probability outcome.
- The group has no material maturities ahead of the senior debt due in February 2028. Operating performance has broadly met or exceeded expectations, aside from a modest Q4 2025 miss, and we see limited risk of negative idiosyncratic developments in the medium term.
- We estimate an enterprise value multiple of 7.5x versus actual leverage of 7.1x as of December 2025. While the company is likely to achieve some of the savings embedded in its pro-forma numbers, current yields do not adequately compensate for the downside risk. Enterprise value coverage remains tight.
Recent Results
- Q4 results came in modestly below our expectations, with a €33m revenue shortfall and EBITDA €6m below forecast. We do not expect this to materially affect near-term trading. We continue to challenge the scale of EBITDA adjustments, which understate leverage in our view: we estimate leverage at c.7.1x versus the company’s reported 5.6x.
- BioGroup uses a FY25 run-rate “leverageable EBITDA” figure of €491m, above both the reported €431m and the €420m adjusted figure we use. The €60m difference includes c.€40m of savings expected in FY26 and €20m in FY27. These savings assume improved purchasing from supplier consolidation (€23m), insourcing previously outsourced testing (€21m), and a combination of overhead reductions, support cost savings, and productivity gains.
- The key issue is that these savings largely offset lower prices imposed by the French state rather than drive margin expansion. In FY25, the company reportedly achieved €61m of incremental EBITDA savings from similar initiatives, yet margins remained broadly flat.
- We expect BioGroup to deliver some of the identified savings; however, we do not expect meaningful EBITDA uplift, as inflation and pricing pressure continue to constrain margins.
Options ahead
- Current trading levels increasingly reflect market expectations that the business may be put up for sale. Press reports have periodically pointed to a potential disposal of BioGroup by the founder’s heir alongside its private equity shareholders. Any such transaction would trigger a change of control, offering an exit opportunity for both bondholders and equity holders.
- However, ongoing sale speculation obscures the growing dependence on delivering a step-change in EBITDA to support a refinancing. On the current EBITDA run-rate and operating cash flow, the capital structure looks tight over the next 18 months. Using a 1.5x interest coverage assumption and a 7% all-in cost of debt, we estimate coverage of the debt stack at approximately 105%. A modest 50bp increase in funding costs would push coverage below 100%.
- When combined with continued uncertainty around the future pricing framework, these dynamics reinforce our view that the risk-reward profile remains skewed to the downside.
Happy to discuss.
Tomás
E: tmannion@sarria.co.uk
T: +44 20 3744 7009
www.sarria.co.uk